DE69432055T2 - Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht - Google Patents

Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht

Info

Publication number
DE69432055T2
DE69432055T2 DE69432055T DE69432055T DE69432055T2 DE 69432055 T2 DE69432055 T2 DE 69432055T2 DE 69432055 T DE69432055 T DE 69432055T DE 69432055 T DE69432055 T DE 69432055T DE 69432055 T2 DE69432055 T2 DE 69432055T2
Authority
DE
Germany
Prior art keywords
permeability
blood
brain barrier
modulating
modules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432055T
Other languages
English (en)
Other versions
DE69432055D1 (de
Inventor
James Martin Staddon
Lawrence Rubin
Kurt Herrenknecht
Louise Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69432055D1 publication Critical patent/DE69432055D1/de
Application granted granted Critical
Publication of DE69432055T2 publication Critical patent/DE69432055T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69432055T 1993-11-19 1994-11-18 Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht Expired - Fee Related DE69432055T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323884A GB9323884D0 (en) 1993-11-19 1993-11-19 Physiological modulation
PCT/GB1994/002543 WO1995013820A1 (en) 1993-11-19 1994-11-18 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier

Publications (2)

Publication Number Publication Date
DE69432055D1 DE69432055D1 (de) 2003-02-27
DE69432055T2 true DE69432055T2 (de) 2003-11-06

Family

ID=10745427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432055T Expired - Fee Related DE69432055T2 (de) 1993-11-19 1994-11-18 Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht

Country Status (7)

Country Link
US (2) US6312686B1 (de)
EP (1) EP0728009B1 (de)
JP (1) JPH09505076A (de)
AT (1) ATE231396T1 (de)
DE (1) DE69432055T2 (de)
GB (1) GB9323884D0 (de)
WO (1) WO1995013820A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423372D0 (en) 1994-11-18 1995-01-11 Eisai London Res Lab Ltd Proteins and their uses
GB9525703D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Screening method
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
AU3378599A (en) * 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US7398119B2 (en) * 1998-07-13 2008-07-08 Childrens Hospital Los Angeles Assessing blood brain barrier dynamics or identifying or measuring selected substances, including ethanol or toxins, in a subject by analyzing Raman spectrum signals
US6574501B2 (en) * 1998-07-13 2003-06-03 Childrens Hospital Los Angeles Assessing blood brain barrier dynamics or identifying or measuring selected substances or toxins in a subject by analyzing Raman spectrum signals of selected regions in the eye
EP1137946B1 (de) * 1998-12-11 2005-10-19 Eisai Co., Ltd. Verwendung des vaskularen endothelialen wachstumsfaktors (vegf)
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6924109B2 (en) * 1999-07-30 2005-08-02 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6841351B2 (en) * 1999-07-30 2005-01-11 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6961599B2 (en) * 2001-01-09 2005-11-01 Childrens Hospital Los Angeles Identifying or measuring selected substances or toxins in a subject using resonant raman signals
JP2004537282A (ja) * 2001-03-23 2004-12-16 エージーワイ セラピューティクス 脳腫瘍の処置及び可視化における生体分子標的の使用法
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
AU2002303804A1 (en) * 2001-05-18 2002-12-03 The Scripps Research Institute Retroviral vectors and methods of using same
GB2396106B (en) * 2002-12-12 2006-11-15 Johnson & Johnson Medical Ltd Wound dressings comprising enzyme inhibitors
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US8529889B2 (en) * 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
GEP20115226B (en) * 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
WO2009114533A2 (en) * 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability
US20130079682A1 (en) * 2011-09-25 2013-03-28 David J. Mischelevich Ultrasound-neuromodulation techniques for control of permeability of the blood-brain barrier
US20130224110A1 (en) * 2010-09-16 2013-08-29 Cornell University Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
CN109432410A (zh) * 2018-12-19 2019-03-08 上海康孕企业管理合伙企业（有限合伙） 血红素在预防和/或改善高原反应的药物、食品及保健食品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494175A4 (en) * 1989-09-27 1993-05-05 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
JPH0413631A (ja) * 1990-04-27 1992-01-17 Tonen Corp アナカルジウム・オクシデンタレ由来の物質
US5155031A (en) * 1990-06-07 1992-10-13 Posner Barry I Use of pervanadate as an inhibitor of phosphotyrosine phosphatase

Also Published As

Publication number Publication date
US20020032151A1 (en) 2002-03-14
US6312686B1 (en) 2001-11-06
EP0728009B1 (de) 2003-01-22
GB9323884D0 (en) 1994-01-05
DE69432055D1 (de) 2003-02-27
WO1995013820A1 (en) 1995-05-26
JPH09505076A (ja) 1997-05-20
EP0728009A1 (de) 1996-08-28
ATE231396T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
DE69432055T2 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
DE69833948D1 (de) Aktives system zur frühen zerstörung von schleppwirbeln
DE3762480D1 (de) Mittel zur applikation von transdermal resorbierbaren wirkstoffen.
DE3674642D1 (de) Zur modifizierung von bitumen verwendbare polymerzusammensetzungen und so modifizierte bitumenmassen.
DE69522301T2 (de) Dichtungsanordnung zur Einführung von chirurgischen Instrumenten
DE69722734T2 (de) Sterile Phiolenverbindung zur Übertragung von Flüssigkeit
DE3751527D1 (de) Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.
DE69841320D1 (de) Verfahren zur modulation von hämatopoese und vaskulärem wachstum
DE3671640D1 (de) Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben.
DE3676601D1 (de) Mittel zur injektion von aktiviertem vitamin-d3.
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
NO20014417D0 (no) Vaskul¶re adhesjonsmolekyler samt modulering av deres funksjon
DE69313823T2 (de) Basischer Lithiumphosphatkatalysator zur Isomerisierung von Alkenoxyden
DE3777878D1 (de) Mittel zur verhinderung des zusammenbackens von duengemitteln.
ATE79255T1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
DE3667912D1 (de) Von bindegewebekulturen abstammendes kosmetisches mittel.
DE69326349T2 (de) Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
FR2783420B1 (fr) Utilisation d'au moins un derive de l'acide 10-hydroxy-2-decenoique dans une composition destinee a favoriser la desquamation de la peau, et composition le comprenant
DE69407583T2 (de) Homogenes katalysator system zur hydrodechlorierung von chlorkohlenwasserstoffen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP

8339 Ceased/non-payment of the annual fee